The biosimilar teriparatide, Terrosa®, has been launched in Europe. The drug is approved in adults for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture as well as for osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
